Literature DB >> 22848256

Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma.

Qian He1, Jiazhang Wei, Jinyan Zhang, Heng Jiang, Shumin Wang, Xiaoying Zhou, Zhe Zhang, Guangwu Huang, Hiroshi Watanabe, Jiping Su.   

Abstract

Secreted protein, acidic and rich in cysteine (SPARC) has been found to be involved in various stages of tumor progression such as migration, invasion, extracellular matrix deposition and angiogenesis. To obtain an insight into the role of SPARC in the progression of laryngeal and hypopharyngeal carcinoma, we investigated SPARC transcription levels and promoter methylation in carcinoma cell lines and primary tumors. Reverse transcription-PCR showed that SPARC was silenced in laryngeal and hypopharyngeal carcinoma cell lines, in which aberrant promoter methylation was detected. Hypermethylation of SPARC was detected in 56.1% (23/41) of laryngeal carcinoma and 70.0% (7/10) of hypopharyngeal carcinoma biopsies, but only in 11.1% (1/9) of normal epithelial specimens by a methylation-specific PCR assay. Bisulphite genomic sequencing indicated that CpG sites in the SPARC promoter were heavily methylated in cell lines and primary tumors. Moreover, pharmacological demethylation treatment rescued SPARC expression with 5-aza-2'-deoxycytidine (5-aza-dC) in the laryngeal carcinoma cell lines. SPARC promoter hypermethylation was significantly correlated with lymph node metastasis (p<0.01). Our findings suggest that hypermethylation of SPARC is a frequent and tumor-specific event in laryngeal and hypopharyngeal carcinomas and may serve as a biomolecular marker for diagnosis and prognosis.

Entities:  

Year:  2011        PMID: 22848256      PMCID: PMC3406334          DOI: 10.3892/ol.2011.297

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  A modified and improved method for bisulphite based cytosine methylation analysis.

Authors:  A Olek; J Oswald; J Walter
Journal:  Nucleic Acids Res       Date:  1996-12-15       Impact factor: 16.971

2.  HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas.

Authors:  Kristi L Bennett; Walter Lee; Eric Lamarre; Xiatong Zhang; Rahul Seth; Joseph Scharpf; Jennifer Hunt; Charis Eng
Journal:  Genes Chromosomes Cancer       Date:  2010-04       Impact factor: 5.006

3.  The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.

Authors:  F Ledda; A I Bravo; S Adris; L Bover; J Mordoh; O L Podhajcer
Journal:  J Invest Dermatol       Date:  1997-02       Impact factor: 8.551

4.  Novel markers for poor prognosis in head and neck cancer.

Authors:  David Chin; Glen M Boyle; Rebecca M Williams; Kaltin Ferguson; Nirmala Pandeya; Julie Pedley; Catherine M Campbell; David R Theile; Peter G Parsons; William B Coman
Journal:  Int J Cancer       Date:  2005-02-20       Impact factor: 7.396

5.  Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas.

Authors:  Toshimoto Seno; Hironobu Harada; Shohei Kohno; Mikio Teraoka; Akihiro Inoue; Takanori Ohnishi
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

6.  A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers.

Authors:  Michelle J Tang; Isabella T Tai
Journal:  J Biol Chem       Date:  2007-09-26       Impact factor: 5.157

7.  Examination of oral cancer biomarkers by tissue microarray analysis.

Authors:  Peter Choi; C Diana Jordan; Eduardo Mendez; John Houck; Bevan Yueh; D Gregory Farwell; Neal Futran; Chu Chen
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-05

8.  Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction.

Authors:  Kazutaka Horie; Masami Tsuchihara; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2009-12-16       Impact factor: 6.716

9.  Aberrant methylation of SPARC in human lung cancers.

Authors:  M Suzuki; C Hao; T Takahashi; H Shigematsu; N Shivapurkar; U G Sathyanarayana; T Iizasa; T Fujisawa; K Hiroshima; A F Gazdar
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

10.  SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.

Authors:  S Cheetham; M J Tang; F Mesak; H Kennecke; D Owen; I T Tai
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640

View more
  3 in total

Review 1.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

2.  Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer.

Authors:  Federico Pio Fabrizio; Angelo Sparaneo; Andrea Fontana; Tommaso Mazza; Paolo Graziano; Angela Pantalone; Paola Parente; Flavia Centra; Natalizia Orlando; Domenico Trombetta; Annamaria la Torre; Gian Maria Ferretti; Marco Taurchini; Concetta Martina Di Micco; Evaristo Maiello; Vito Michele Fazio; Antonio Rossi; Lucia Anna Muscarella
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

3.  Outlier Analysis Defines Zinc Finger Gene Family DNA Methylation in Tumors and Saliva of Head and Neck Cancer Patients.

Authors:  Daria A Gaykalova; Rajita Vatapalli; Yingying Wei; Hua-Ling Tsai; Hao Wang; Chi Zhang; Patrick T Hennessey; Theresa Guo; Marietta Tan; Ryan Li; Julie Ahn; Zubair Khan; William H Westra; Justin A Bishop; David Zaboli; Wayne M Koch; Tanbir Khan; Michael F Ochs; Joseph A Califano
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.